Multiple Myeloma Hub

The Multiple Myeloma Hub spoke to Irene Ghobrial, Dana-Farber Cancer Institute, Boston, US. We asked about risk stratification and prognosis in smoldering multiple myeloma (MM). During this interview, Ghobrial discussed risk stratification and prognosis in smoldering MM, with a focus on whether high-risk smoldering MM should be treated early. Ghobrial emphasized the heterogeneity of the condition,...

The Multiple Myeloma Hub spoke with Alexander Lesokhin, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What combination regimens containing B-cell maturation antigen (BCMA)-directed bispecific antibodies are being evaluated for multiple myeloma (MM)? In this interview, Lesokhin discussed the range of combination regimens featuring a BCMA-directed bispecific antibody for MM, outlin...

The Multiple Myeloma Hub spoke with Peter Forsberg, Colorado Blood Cancer Institute, Denver, US. We asked, How can neurotoxicity associated with chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM) be managed?    In this interview, Dr Forsberg explored the evolving understanding and management of neurotoxicity associated with CAR T-cell therapy in MM. Forsberg highligh...

The Multiple Myeloma Hub spoke with Sagar Lonial, Winship Cancer Institute of Emory University, Atlanta, US. We asked, What might be the future applications for B-cell maturation antigen (BCMA)-directed bispecific antibodies in multiple myeloma (MM) and other plasma cell dyscrasias? In this interview, Sagar Lonial discussed the expanding role of BCMA-directed bispecific antibody therapies beyond r...

The Multiple Myeloma Hub spoke with Shaji Kumar, Mayo Clinic, Rochester, US. We asked about the future perspectives for the treatment of patients with high-risk smoldering multiple myeloma (MM).    In this interview, Dr Kumar explored the emerging treatment landscape for high-risk smoldering MM, highlighting a shift from active monitoring to intervention. Kumar discussed the increasing e...

The Multiple Myeloma Hub was pleased to speak with Hang Quach, St Vincent’s Hospital Melbourne and University of Melbourne, Melbourne, AU. We asked, How are B-cell maturation antigen (BCMA)-directed bispecific antibodies currently utilized in real-world practice for multiple myeloma (MM)?  In this interview, Professor Quach discussed how the development and integration of BCMA-directed bispec...

During the Multiple Myeloma Hub Steering Committee Meeting in April 2025, key opinion leaders met to discuss the implications of measurable residual disease (MRD) on clinical practice and trial design in multiple myeloma (MM). The meeting opened with a presentation by Bruno Paiva and featured a discussion including Paul Richardson, Hang Quach, Sonja Zweegman, and Rakesh Popat.     D...

During the Multiple Myeloma Hub Steering Committee Meeting in April 2025, key opinion leaders met to discuss exportin 1 (XPO1) as a target for the treatment of multiple myeloma (MM) with a focus on real-world evidence. The meeting opened with a presentation by Paul Richardson and featured a discussion including María-Victoria Mateos, Hang Quach, and Morie Gertz. In the presentation, Dr Richardson...

This educational resource is independently supported by GSK. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.  The Multiple Myeloma Hub spoke with Rakesh Popat, University College Hospital, London, UK. We asked, How to incorporate novel therapies into the treatment paradigm for early relapse...

In this interview, Hermann Einsele discusses the future perspectives of anti-CD38 antibodies, highlighting their role in first-line treatment for both transplant-eligible and -ineligible patients as well as applications in the second line and smoldering MM. Einsele also discusses outcomes from key trials and outlines potential combinations of anti-CD38s with emerging therapies, including cereblon...

This educational resource is independently supported by GSK. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource. The Multiple Myeloma Hub was pleased to speak with Rahul Banerjee, Fred Hutchinson Cancer Research Center, Seattle, US. We asked about the current treatment recommendations and unmet need...

The Multiple Myeloma Hub spoke to Sagar Lonial, Winship Cancer Institute of Emory University, Atlanta, US. We asked, What is the rationale for treating early relapsed/refractory multiple myeloma (RRMM) with targeted therapies?   In this interview, Lonial discusses how the treatment landscape for early RRMM has changed over time, impacting the effectiveness of standard of care therapies and le...

The Multiple Myeloma Hub spoke to Vania Tietsche de Moraes Hungria, Clínica São Germano, São Paolo, BR. We asked, What is the impact of belantamab mafodotin (belamaf) on quality of life (QoL) in patients with multiple myeloma (MM)?   Hungria provided insights into the mechanism of action of belamaf, its efficacy and safety in heavily pre-treated patients, and the latest findings from the phas...

The Multiple Myeloma Hub spoke with Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR. We asked, What is the impact of elranatamab on quality of life (QoL) in relapsed/refractory multiple myeloma (RRMM)?  Mohty discussed the impact of elranatamab on QoL in patients with RRMM, highlighting its benefits in symptom relief, mobility, and overall well-being. Mohty also addres...

During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint satellite symposium entitled ‘Sequencing immune-based therapies in B-cell malignancies’. Here the Multiple Myeloma Hub is pleased to share the session: Next wave of immune-based therapies: What you need to know, which focused on relapsed/refractory (R/R) multiple myeloma (M...

Ciltacabtagene autoleucel (cilta-cel) is a B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T-cell therapy, which is one of only two U.S. Food and Drug Administration (FDA)-approved CAR T-cell therapies for the treatment of relapsed/refractory multiple myeloma (RRMM). Both approved CAR T-cell agents are indicated in the heavily pre-treated setting after four or more prior...

During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint satellite symposium entitled ‘Sequencing immune-based therapies in B-cell malignancies’. Here, the Multiple Myeloma Hub is pleased to share the session, which covered how to sequence CAR T-cell therapy and bispecific antibodies in relapsed/refractory (R/R) multiple myeloma...

During the 65th American Society of Hematology Annual Meeting and Exposition, Dima presented results from a retrospective analysis to evaluate the real-world safety and efficacy of teclistamab, with a focus on patients who would have been ineligible for the MajesTEC-1 trial. We summarize the key findings in this podcast. To read this article on the Multiple Myeloma Hub, click here: https://multipl...

During the Multiple Myeloma Hub Steering Committee Meeting in May 2024, key opinion leaders met to discuss key considerations regarding infections associated with bispecific antibodies. Meral Beksaç​ opened with a presentation reviewing the infectious complications associated with bispecific antibodies, and current treatment algorithms for such infections. Beksaç​ explored an analysis of infection...

During the Multiple Myeloma Hub Steering Committee Meeting in May 2024, key opinion leaders met to discuss the current use of CAR T-cell therapies in clinical practice, with a focus on patient-specific considerations in the development of personalized treatment plans.  To open, Hermann Einsele provides a presentation reviewing the latest data from trials of ciltacabtagene autoleucel (cilta-ce...

The Multiple Myeloma Hub was pleased to speak to Shaji Kumar, Mayo Clinic, Rochester, US, and Naresh Bumma, The Ohio State University, Columbus, US. We asked, How to select maintenance therapies post-autologous stem cell transplant (ASCT) for patients with high-risk MM? In this expert discussion, Shaji Kumar and Naresh Bumma provide their insights into post-ASCT maintenance therapy for high-risk p...

The Multiple Myeloma Hub was pleased to speak to Hira Mian, McMaster University, Hamilton, CA. We asked, Should risk-adapted MM treatment be informed by age or frailty status? In this podcast, Hira Mian discusses the relationship between age and frailty status, sharing her perspective on how they may inform treatment strategies for patients with multiple myeloma. Mian examines the influence of age...

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Timothy Schmidt, University of Wisconsin-Madison, Madison, US. We asked, How is the immune reconstitution in patients who stop therapy after achieving minimal residual disease (MRD) negativity? In this interview, Schmidt discusses their poster presented at ASH 2022 e...

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Vania Tietsche de Moraes Hungria, Clínica São Germano, São Paulo, BR. We asked, What are the main discrepancies between multiple myeloma (MM) treating centers in Brazil? In this podcast, Hungria discusses their poster presented at ASH 2022 entitled: A Brazilian real-...

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Meral Beksac, Ankara University, Ankara, TR. We asked, What are the initial data of dara-CyBorD in patients with extramedullary disease? In this podcast, Beksac discusses their poster presented at ASH 2022 entitled: Efficacy of daratumumab combined with bortezomib, c...